Cardiac Protection by Basic Fibroblast Growth Factor from Ischemia/Reperfusion-Induced Injury in Diabetic Rats

Abstract

Diabetes impairs the expression and function of endogenous growth factors, leading to increased cardiovascular events in diabetic patients. Supplementation of fibroblast growth factors (FGFs) protected the heart from ischemia/reperfusion (I/R)-induced injury in animal models. However, it has not yet been tested in diabetic heart. The present study was thus to clarify whether basic fibroblast growth factor (bFGF) could protect the heart from I/R-induced damage under diabetic conditions using a rat model. Male Sprague Dawley rats were used to induce diabetes by intraperitoneal injection of streptozotocin. Eight weeks later, I/R injury was generated in diabetic rats and age-matched non-diabetic rats. All I/R rats were administrated bFGF or saline through intramyocardial injection. Seven days after I/R, cardiac infarction, structural changes, cell death and blood vessel density, serum malondialdehyde (MDA) and cardiac enzyme lactate dehydrogenase (LDH) were examined. We found that I/R induced significant increases in the cardiac infarction, blood MDA contents and LDH activities, and the expression of caspase-3. Treatment of I/R rats with bFGF simultaneously with reperfusion significantly attenuated I/Rinduced pathological changes, along with a significant increase in the cardiac blood vessel density in both diabetic and non-diabetic rates. The protective effects of bFGF on I/R-induced cardiac injury in diabetic group are less than those in non-diabetic group. The results indicated that bFGF provide a protection of the heart against I/R-induced oxidative damage, cell death and infarction under diabetic conditions.

Induced Pluripotent Stem Cells Without c-Myc Ameliorate Retinal Oxidative Damage via Paracrine Effects and Reduced Oxidative Stress in Rats

“…conditions. 30 In a previous study, we have shown that cultured iPSCs can secrete bFGF in vitro. 31 In this study, we demonstrated that the levels of bFGF did not significantly increase at day 3 but did reach significance later, at days 7, 14, and 21, while SDF-1a was upregulated early, at day 3 after iPSC transplantation.…”

Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction

“…3 Acidic fibroblast growth factor (aFGF) is an important member of the FGF family, with a wide range of biological functions, including mitogenic and non-mitogenic activities, and it is expressed at high levels in the heart. 4,5 However, aFGF has powerful mitogenic and proliferative influences and produces negative effects, such as tumor genesis and metastasis. 6,7 Previous studies have shown that aFGF protects the cardiac function in myocardial diseases, such as diabetic cardiomyopathy and post-ischemic reperfusion, with its nonmitogenic activities.…”

Prevention of Diabetic Nephropathy by Modified Acidic Fibroblast Growth Factor

“…Diabetic nephropathy (DN) is associated with hemodynamic and metabolic perturbations caused by hyperglycemia, leading to the development of functional and morphological abnormalities [1][2][3][4] . Oxidative stress (OS) and subsequent cellular damage are postulated to play crucial roles, leading to the development of glomerular and renal injury [5,6] .…”